Edoardo Profile
Edoardo

@EdoGal89

Followers
159
Following
2K
Media
125
Statuses
2K

Joined March 2012
Don't wanna be here? Send us removal request.
@EdoGal89
Edoardo
6 years
Is this for real?! Thanks to all my coauthors, collaborators and friends @BecherLab, and @NatureMedicine of course. Another step closer to the understanding of #MultipleSclerosis, aiming to provide a better care for these patients.
Tweet card summary image
nature.com
Nature Medicine - A machine learning approach using high-dimensional phenotypic and functional profiling data identifies a multiple sclerosis-specific T cell population that is reduced following...
0
3
15
@NEJM
NEJM
1 month
Original Article: Common Diseases in Clinical Cohorts — Not Always What They Seem https://t.co/PBk8feriL4 Editorial: A Rare-in-Common Paradigm for Precision Genomic Medicine https://t.co/wKXF0QInBB #Genetics
0
11
48
@ECTRIMS
ECTRIMS
2 months
Don’t miss our post #ECTRIMS2025 abstract webinar happening TODAY at 13:00 CEST - featuring one standout abstract from each track — Clinical, Therapy, Pathogenesis, & Imaging & Non-imaging Biomarkers 👉 Secure your spot: https://t.co/KSdPpUqGVE Moderators: Stefan Bittner from
0
1
8
@ECTRIMS
ECTRIMS
3 months
📢 Breaking news: The 2024 revised #McDonaldCriteria have been published in @TheLancetNeuro. Explore the latest evidence shaping #MSDiagnosis. Published by the International Advisory Committee for Clinical Trials in #MS. 👉 https://t.co/8V2lWodMm2 @mssociety #MSResearch #IACCTMS
3
18
54
@EdoGal89
Edoardo
3 months
Brilliant approach with terrific implications in clinical MS. Chapeau
@hwiendl
Heinz Wiendl
3 months
🚨 Paradigm shift in #MultipleSclerosis 🚨 New study in Nature Medicine shows MS is not fixed subtypes but a dynamic continuum of states across 4 dimensions: disability, brain damage, relapses & silent inflammation. 📖 Read: https://t.co/MYvAAI6AiV #MS #Neurology #AI
0
0
1
@ECTRIMS
ECTRIMS
4 months
Are you a researcher or healthcare professional (HCP) under 40 or in your early career who's attending #ECTRIMS2025 in Barcelona? Join the Young #MS HCP & Researcher Networking Event! 🗓️ 24 Sep 2025, 18:45-20:30 CEST 📍 NeuroNetwork Sign up for free 👉 https://t.co/5DpYXGfiK4
0
4
5
@ECTRIMS
ECTRIMS
5 months
🎓 Webcasts from our Summer School in Stockholm this June are now available on #myECTRIMS! Gain insights from leading experts on Visual System Evaluation in #MS and Other Demyelinating Diseases. Watch them here: https://t.co/ZZx9ZubXn0 #ECTRIMSNextGen #MultipleSclerosis
0
2
13
@NEJM
NEJM
5 months
In the latest video in our partnership with @DGlaucomflecken, the BALANCE trial comparing 7 days of antibiotic treatment with 14 days of treatment in patients with bloodstream infection is explained. Access the article for free: https://t.co/A7Z3do3VF6
23
183
779
@ECTRIMS
ECTRIMS
5 months
📢 Last call! Are you an early career #MS professional looking for guidance and support? Join the #ECTRIMS #Mentorship Programme! #ECTRIMSNextGen ✅ Sign up as a mentee and get matched ➡️ https://t.co/VaTyjH4ahh Deadline: 30 June.
0
2
3
@EdoGal89
Edoardo
6 months
Long due but incredibly welcome step forward in MS! A major milestone that will massively impact every aspect of how we understand and treat MS, from trial design to targeting specific biological drivers of disease. Exciting times ahead! #Neuroimmunology #RC2NB #ECTRIMS
@ECTRIMS
ECTRIMS
6 months
The International Advisory Committee on Clinical Trials in #MS met in May to discuss a topic that could reshape the landscape of MS care and research: the revision of MS course descriptors. Learn why this is an important step forward in #MSResearch: ➡️ https://t.co/zsQB5GY1b9
0
1
3
@ECTRIMS
ECTRIMS
7 months
🧬Why do some people develop MS while others do not? No single genetic variant alone can cause MS. Each one adds incrementally to the overall risk – an effect known as polygenicity. Discover more in our latest Spotlight 👉 https://t.co/hcMYK4NXdH #MS #Genetics
0
2
4
@ECTRIMS
ECTRIMS
7 months
NEW! myECTRIMS now has a #Mentorship Programme for early-career healthcare professional looking for guidance and support. Get matched with an experienced mentor and build valuable connections for your future. ✅ Sign up as a mentee here: https://t.co/VaTyjH4ahh
0
1
3
@giuliocavalli
Giulio Cavalli
8 months
La "liberazione"
1
11
28
@ECTRIMS
ECTRIMS
10 months
🚀 Something exciting is on the horizon at ECTRIMS! Over the last year we’ve been working behind the scenes to build a personalised and seamless ECTRIMS experience designed just for you. Stay tuned—myECTRIMS is coming soon!
0
5
18
@EdoGal89
Edoardo
1 year
Congratulations @JensKuhle !
@RC2NB
RC2NB
1 year
Ending the Year on a High Note! Prof. @JensKuhle (@UniSpitalBasel) has been awarded the Sobek Foundation Award 2024, Europe’s most prestigious honor in MS research! A remarkable recognition for his work on biomarkers transforming MS care. @UniBasel_en #MultipleSclerosis
0
0
0
@ECTRIMS
ECTRIMS
1 year
At ECTRIMS, we are privileged to carry forward Professor Giancarlo Comi’s work, honor his legacy, and pursue his vision. Read ECTRIMS’ tribute to his remarkable career: https://t.co/WSd8fKWvuS
0
6
35
@EdoGal89
Edoardo
1 year
Congratulations! Very cool!
0
0
2
@Brandon_Beaber
Dr. Brandon Beaber
1 year
Does checking neurofilament light chain (sNfL) help guide personalized treatment of MS and lead to better outcomes? We'll find out soon. This Swiss Randomized trial will but the biomarker to the test.
Tweet card summary image
pubmed.ncbi.nlm.nih.gov
ClinicalTrials.gov NCT06095271. Registered on October 23, 2023.
0
1
17
@LabListon
Adrian Liston
1 year
Biggest paper yet from the lab out now in @ImmunityCP! It is a massive #openscience resource on #tissueTregs, and what makes #Tregs tick in the #tissues. Spoiler-alert: Tissue Tregs are really different from what we all thought. 🧵 1/21 https://t.co/k8q7LhMewB
19
131
507
@ECTRIMS
ECTRIMS
2 years
Early Bird Registration Still Open for #ECTRIMS2024! Secure your ticket for the leading #MultipleSclerosis congress in Copenhagen from 18-20 September. Save substantially by acting now! Early bird pricing ends on 24 July. Register today ➡️ https://t.co/Q7n7LlV6Zv
0
1
2